All Clinical Trials
Filter by Category
- All Clinical Trials
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
Official Title Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Phase Phase II
ClinicalTrials.gov NCT01359644
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb; Pharmasset (Gilead Sciences)
References
- Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21.
Official Title Daclatasvir with Sofosbuvir and Ribavirin for Hepatitis C Virus Infection with Advanced Cirrhosis or Post-Liver Transplantation Recurrence
Phase Phase III
ClinicalTrials.gov NCT02032875
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493-505.
Official Title Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Phase Phase III
ClinicalTrials.gov NCT02032888
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714-25.
Official Title All-Oral 12-Week Treatment with Daclatasvir plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
Phase Phase III
ClinicalTrials.gov NCT02032901
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-35.
Official Title Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III study (ALLY-3+)
Phase Phase III
ClinicalTrials.gov NCT02319031
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430-41.
Official Title Daclatasvir plus Peginterferon Alfa and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 1 or 4 Infection: A Randomised Study
Phase Phase II
ClinicalTrials.gov NCT01125189
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948-56.
Official Title Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4)
Phase Phase III
ClinicalTrials.gov NCT01448044
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Hézode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015;21:195-205.
Official Title All-Oral Daclatasvir plus Asunaprevir for Hepatitis C Virus Genotype 1b: A Multinational, Phase 3, Multicohort Study
Phase Phase III
ClinicalTrials.gov NCT01581203
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597-605.
Official Title Daclatasvir and Asunaprevir plus Peginterferon Alfa and Ribavirin in HCV Genotype 1 or 4 Non-Responders
Phase Phase III
ClinicalTrials.gov NCT01573351
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Jensen D, Sherman KE, Hézode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63:30-7.
Official Title Fixed-Dose Combination Therapy with Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients with HCV Genotype 1 Infection
Phase Phase III
ClinicalTrials.gov NCT01979939
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728-35.
Official Title Daclatasvir in Combination with Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection with Compensated Cirrhosis
Phase Phase III
ClinicalTrials.gov NCT01973049
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb
References
- Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736-44.